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Abstract
Lynch syndrome is caused by germline mutations of DNA mismatch repair (MMR) genes,
most frequentlyMLH1 andMSH2. Recently, MMR-deficient crypt foci (MMR-DCF) have
been identified as a novel lesion which occurs at high frequency in the intestinal mucosa
from Lynch syndrome mutation carriers, but very rarely progress to cancer. To shed light on
molecular alterations and clinical associations of MMR-DCF, we systematically searched
the intestinal mucosa from Lynch syndrome patients for MMR-DCF by immunohistochemis-
try. The identified lesions were characterised for alterations in microsatellite-bearing genes
with proven or suspected role in malignant transformation. We demonstrate that the preva-
lence of MMR-DCF (mean 0.84 MMR-DCF per 1 cm2 mucosa in the colorectum of Lynch
syndrome patients) was significantly associated with patients’ age, but not with patients’
gender. No MMR-DCF were detectable in the mucosa of patients with sporadic MSI-H colo-
rectal cancer (n = 12). Microsatellite instability of at least one tested marker was detected in
89% of the MMR-DCF examined, indicating an immediate onset of microsatellite instability
after MMR gene inactivation. Coding microsatellite mutations were most frequent in the
genes HT001 (ASTE1) with 33%, followed by AIM2 (17%) and BAX (10%). Though MMR
deficiency alone appears to be insufficient for malignant transformation, it leads to measur-
able microsatellite instability even in single MMR-deficient crypts. Our data indicate for the
first time that the frequency of MMR-DCF increases with patients’ age. Similar patterns of
coding microsatellite instability in MMR-DCF and MMR-deficient cancers suggest that cer-
tain combinations of coding microsatellite mutations, including mutations of the HT001,
AIM2 and BAX gene, may contribute to the progression of MMR-deficient lesions into MMR-
deficient cancers.
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Introduction
Lynch syndrome, occurring with an estimated allele frequency of up to 1:350, is one of the
most common inherited cancer syndromes [1] and clinically often referred to as hereditary
non-polyposis colorectal cancer (HNPCC) [2]. Lynch syndrome mutation carriers have a life-
time risk of about 40% to 80% to develop colorectal cancer [3,4].
Tumorigenesis in Lynch syndrome-associated malignancies is caused by deficiency of one
of the DNAMMR genes, such asMLH1,MSH2, PMS2 andMSH6 [5]. Carriers of a germline
mutation in one allele of the respective MMR gene acquire a second somatic mutation that in-
activates the remaining functional allele of the MMR gene, following the classical two-hit hy-
pothesis [6]. Inactivation of MMR genes consequently leads to the loss of MMR protein
expression in tumour cells and to an MSI-H phenotype. This phenomenon can be detected by
immunohistochemistry [7,8] and thus point to the appropriate MMR gene for mutation
analysis.
A feature characteristic of Lynch syndrome is the lack of polyposis, which is in sharp con-
trast to other inherited colorectal cancer-predisposing syndromes like the familial adenoma-
tous polyposis [9–11]. Recently, MMR-DCF have been described as a non-polypous
morphologic correlate of somatic MMR gene inactivation in Lynch syndrome [12]. MMR-DCF
occur at thousands in otherwise phenotypically normal intestinal mucosa of Lynch syndrome
mutation carriers [12]. This is in contrast to the limited penetrance of Lynch syndrome and in-
dicates that MMR-DCF only rarely progress to cancer. However, the natural history of
MMR-DCF, as well as their association with clinical parameters and their molecular character-
istics, are completely unknown.
At advanced stages of tumour progression, MMR deficiency can promote tumour develop-
ment through mutations affecting microsatellites located in gene-encoding regions that are es-
sential for growth regulation, differentiation or apoptosis [13–15]. Certain coding
microsatellite-bearing target genes have been proven or suspected to have functional relevance
in MSI-H colorectal cancer. These include ACVR2 (activin receptor type 2), TAF1B (TATA
box binding protein-associated factor) and HT001, also known as ASTE1 (asteroid homolog 1),
which show mutation rates of more than 80% in MSI-H colorectal cancer [15–18]. Also AIM2
(absent in melanoma 2), and the pro-apoptotic BAX (BCL2-associated X protein) are inacti-
vated by coding microsatellite mutations in the majority of MSI-H colorectal cancer [19–21].
The most prominent example of a functionally relevant target gene in MSI-H colorectal cancer,
is the TGFBR2 (transforming growth factor receptor type 2) gene [22] which bears a coding mi-
crosatellite of ten adenosine residues frequently targeted by MMR gene inactivation.
In the present study, we aimed to characterise the clinical and molecular characteristics of
MMR-DCF as possible cancer precursor lesions in Lynch syndrome. To that end, we correlated
the occurrence of MMR-DCF with clinical parameters like patients’ age, gender, and MMR
gene germline mutation. In order to identify the consequences of MMR deficiency with poten-
tial functional significance in MMR-DCF, we focused on potential driver mutations in selected
coding microsatellite-bearing target genes.
Materials and Methods
Samples of patient cohorts and controls
Paraffin-embedded archival tissues from small and large bowel (270 paraffin blocks) from
Lynch syndrome patients (n = 34) operated for colorectal cancer were retrieved from the ar-
chive of the Institute of Pathology University Hospital Heidelberg, Heidelberg, Germany. Re-
sections had been performed between 1999 and 2011. Non-tumorous mucosa from the
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resection margins and from tumour-adjacent non-neoplastic tissue was analysed for changes
in MMR protein expression (MLH1, MSH2, and MSH6). Of the 34 Lynch syndrome patients,
19 showed aMLH1mutation, 14 aMSH2mutation and one patient presented with aMSH6
mutation. In addition non-tumorous mucosa was analysed from patients with sporadic MMR-
deficient cancers caused byMLH1 promoter methylation (n = 12). Moreover, control staining
with an antibody specific for an MMR protein not affected by a germline mutation was per-
formed in 5 of the Lynch syndrome patients and one MSS control patient. For correlation anal-
ysis with clinical parameters, the cohort was enlarged by including 10 patients (LS 1–10; 4 with
MLH1 and 6 with aMSH2mutation) and 9 controls (patients with MMR-proficient colorectal
cancer) published in our previous study [12]. The study was approved by the Ethics Committee
of the University Hospital Heidelberg. All patients provided informed and written consent for
participation in the study of the German HNPCC Consortium.
All blocks were cut into ten serial sections of 2 μm each. The fifth slide was chosen for MMR
protein immunohistochemistry, three adjacent slides were used for manual microdissection
and four slides were stained with antibodies against immune cell markers. These slides together
with the fifth one were scanned using the Nanozoomer 2.0-HT Scansystem at the Hamamatsu
TIGA Center (BioQuant, Heidelberg) for analysis and later also used for microdissection.
Immunohistochemistry and length measurement
Immunohistochemistry was performed on 2 μm paraffin sections by using monoclonal anti-
bodies specific for MLH1 (clone G168-15, dilution 1:25, BD Pharmingen, Heidelberg, Ger-
many), MSH2 (clone FE11, dilution 1:200, Calbiochem, Darmstadt, Germany) or MSH6
(clone44, dilution 1:50, Cell Marque, Rocklin, USA) for detecting loss of MMR protein as de-
scribed previously [12]. An immunoperoxidase method was used to visualise the antibodies by
labelling them with a chromogen (3-amino-9-ethylcarbazole, Dako, Glostrup, Denmark). The
amount of mucosal length and surface analysed was calculated as described previously [12].
For immunohistochemical staining of immune cells in the vicinity of MMR-DCF the fol-
lowing antibodies were used: CD4 (clone RPA-T4, dilution 1:50, BD Pharmingen, Heidelberg,
Germany), CD8 (clone 4B11, dilution 1:50, Novocastra, Wetzlar, Germany) and FoxP3 (clone
236A/E7, dilution 1:50, eBioscience, Frankfurt, Germany).
Immune cell infiltration was qualitatively assessed by two independent observers.
PCR and direct microdissection
Nine microsatellite markers were examined in MMR-DCF and normal MMR-proficient intes-
tinal crypts by PCR using Platinum Taq Polymerase (Invitrogen, Life technologies, Darmstadt,
Germany). For each PCR, the master mix was prepared as follows: 2.5 μl of 10 x buffer, 0.75 μl
of 50 mMMgCl2, 5 μl of 1.25 mM dNTPs, 0.2 μl of Taq polymerase, two or three primer pairs
in different dilutions (see below) and RNAse-free water ad 25 μl. Template was added to the
PCR mastermix by direct manual microdissection from immunohistochemically or haematox-
ylin/eosin-stained sections of MMR-DCF and control crypts.
To increase the number of evaluated genes bearing coding or non-coding microsatellites,
different duplex or triplex PCRs were performed using the following primer combinations: Ap-
proach 1: AIM2 (1 μl per primer), ACVR2 (3 μl); Approach 2: BAX (1 μl), HT001 (2 μl); Ap-
proach 3: TGFBR2 (1 μl), TAF1B (1 μl); Approach 4: BAT25 (0.7 μl), BAT26 (1 μl) and CAT25
(1.3 μl). For approaches 1–3 cycling conditions were as follows: 5 min at 94°C; 40 cycles: 52 s at
94°C, 66 s at 56°C, 44 s at 72°C; 6 min at 72°C. For approach 4, cycling conditions were identi-
cal except for the annealing temperature (55°C). Coding microsatellites located within a gene
are referred to by the name of the gene throughout the manuscript.
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PCR products were separated on an ABI3100 sequencer (Applied Biosystems, Darmstadt,
Germany), and fragment lengths were identified with the GeneMapper software 5 (Release 5.0,
Applied Biosystems, Darmstadt, Germany). As a control for the molecular analyses, an addi-
tional set of 7 MSS colorectal cancer patients was included in the microdissection approach
Statistical analysis
Since the surface area and the crypt numbers were estimated as functions of mucosal length,
the statistical analysis of the number of MMR-DCF was performed with respect to the assessed
mucosal lengths only. Based on the assumption that the number of MMR-DCF follows a Pois-
son distribution, a Poisson regression model was applied to analyse the occurrence of crypt foci
with respect to mucosal length, tumour localisation, germline mutation, age and gender. Mod-
els were checked for overdispersion and zero inflation. Expected counts and incident rate ratios
together with their corresponding 95% confidence intervals (95% CIs) were computed to illus-
trate the results. Fisher’s exact test was used to compare mutation frequencies of the analysed
microsatellite markers in MMR-DCF and controls. For all statistical tests undertaken, a result
was regarded significant with a p-value<0.05.
Results
Frequency and clinical distribution
In total, MMR protein immunohistochemistry was performed in 714 cm of mucosa (626 cm
large bowel, 88 cm small bowel) from carriers of a Lynch syndrome mutation and 144 cm (129
cm large bowel, 15 cm small bowel) from patients without a germline mutation in the respec-
tive MMR gene, including 62 cm of mucosa (49 cm large bowel, 13 cm small bowel) from pa-
tients with sporadic MSI-H colorectal cancer. This corresponds to the following surface areas:
24.9 cm2 mucosa from Lynch syndrome mutation carriers (22.5 cm2 large bowel, 2.4 cm2 small
bowel) and 5.1 cm2 from patients without an MMR gene germline mutation (4.7 cm2 large
bowel, 0.4 cm2 small bowel), including 2.2 cm2 from sporadic MSI-H colorectal cancer patients
(1.8 cm2 large bowel, 0.4 cm2 small bowel).
In sections from Lynch syndrome patients, immunohistochemistry for MLH1, MSH2 and
MSH6 revealed 21 crypt foci lacking the expression of the respective MMR protein (Fig. 1A).
The MMR-DCF always showed loss of the MMR protein corresponding to the respective
MMR gene germline mutation of the patient. MMR-DCF were identified in the large bowel
mucosa of 9 patients and in the small bowel mucosa of 2 patients. Among patients who did not
display any MMR-DCF, the maximal length analysed was 28 cm (approximately 1 cm2); the
minimal length analysed in MMR-DCF-positive patients was 6 cm (0.17 cm2) in the small
bowel and 8 cm in the colon (0.29 cm2).
Overall, the frequency of MMR-DCF in Lynch syndrome mutation carriers was 0.84 foci/cm2
(19 foci/22.5 cm2) in the colon and 0.83 foci/cm2 (2 foci/2.4 cm2) in the small bowel. No signifi-
cant difference of MMR-DCF frequency was observed betweenMLH1 and MSH2 germline mu-
tation carriers. NoMMR-DCF were found in 62 cm (approximately 2.2 cm2) mucosa of all 12
patients with sporadic MLH1-hypermethylated MSI-H colorectal cancer patients or in 82 cm
(approximately 3 cm2) of the control patients without germline mutations of the respective
MMR gene.
Association with clinical parameters
As a next step, a potential correlation of MMR-DCF in the colorectum with tumour localisa-
tion, gender and age was addressed. MMR-DCF were significantly more frequent in patients
Mismatch Repair-Deficient Crypt Foci in Lynch Syndrome
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with cancer of the distal colorectum (left colonic flexure or more distal, n = 7) compared to pa-
tients with proximal colon cancer (n = 22) (2.38 MMR-DCF per 50 cm [1.8 cm2] in the distal
colorectum, 95% CI 0.57–4.19, vs. 0.55 MMR-DCF per 50 cm [1.8 cm2] in the proximal colon,
95% CI 0.19–0.92, p = 0.008). Patients from both groups, proximal and distal tumour localisa-
tion, did not significantly vary concerning parameters such as age and gender (proximal tu-
mour localisation, median age: 44 years, 23% female; distal tumour localisation, median age: 45
years, 14% female).
To examine the correlation between prevalence of colorectal MMR-DCF and age or gender,
combined analyses encompassing previously published patients [12] were performed. There was
no significant association of MMR-DCF prevalence with gender (1.05 MMR-DCF per 50 cm
[1.8 cm2] in females, 95% CI 0.19–1.92, vs. 0.96 MMR-DCF per 50 cm [1.8 cm2] in males, 95%
CI 0.57–1.35, p = 0.85). However, the prevalence of colorectal MMR-DCF was significantly relat-
ed to the age of the patient at the time of the operation (p<0.001). Based on the results of the
Poisson regression model, the estimated incident rate ratio of colorectal MMR-DCF was 1.75
(95% CI 1.30–2.35) for a change of age at operation of 10 years. This corresponds to a number of
predicted MMR-DCF per 50 cm (1.8 cm2) mucosa of 0.59 (95% CI 0.27–0.90) at an age of 40,
and 1.03 (95% CI 0.64–1.42) per 50 cm (1.8 cm2) at an age of 50, respectively (Fig. 2).
Morphology
To obtain larger amounts of DNA and more MMR-DCF for morphologic and molecular analy-
sis, paraffin blocks from five of the patients that had revealed MMR-DCF in the first round of
staining were resectioned. Using this method, six novel, independent MMR-DCF were identi-
fied and included in the molecular analysis. The crypt foci detected in our study displayed a
varying size from one to nine crypts. Seven of the now 27 MMR-DCF (4/15 monocryptic, 1/9
oligocryptic and 2/3 polycryptic) presented with dysplastic changes but none showed a poly-
pous or adenomatous appearance. The remaining 20 foci were morphologically undistinguish-
able from their neighbouring crypts except for their absence of MMR protein expression.
Morphological characterisation of MMR-DCF-adjacent mucosal areas after haematoxylin/
eosin and immunohistochemistry staining specific for T cell markers including CD4, CD8 and
FOXP3 did not reveal signs of an altered immune infiltration in or around any of the
MMR-DCF assessed (S4 Fig.).
Molecular alterations in MMR-DCF
For molecular characterisation of the detected MMR-DCF, we analysed three non-coding and
six coding microsatellite markers located in genes proven or suspected to be relevant for tu-
mour formation. Mutation patterns in MMR-DCF were compared to MMR-proficient crypts
from Lynch syndrome mutation carriers or MSS colorectal cancer control patients.
The general comparison of microsatellite mutation frequency revealed a significantly higher
number of mutation events in MMR-DCF than in MMR-proficient crypts, when all markers
Fig 1. Histology andmolecular phenotype of representative MMR-DCF. (A) Staining of three representative MMR-DCF. Objective magnification is 20x
for all panels. Representative staining results with antibodies specific for the MMR protein corresponding to the germline mutation of the respective patient.
Lesions are denoted by patient ID (LYS = Lynch syndrome patient) and lesion ID. (B) Fragment length analysis of triplex PCR with BAT25, BAT26 and
CAT25. Compared to two normal intestinal crypts analysed as a reference (lower panels), all three markers show deletion mutations in the examined
MMR-DCF (LYS 21, Lesion 1). Deletion mutations are indicated by red arrows in MMR-DCF (upper panel: BAT25, green peaks, -3; BAT26, filled blue peaks,
-2; CAT25, open blue peaks, -1). (C) Fragment length analysis of duplex PCR with BAX andHT001 of patient LYS 19. Depiction of an HT001 (right sided
fragments) mononucleotide shift (-1, red arrow) as an example of a coding microsatellite-bearing target gene mutation. The fragment analysis is directly
compared to the results obtained from two normal intestinal crypts of the same patient (lower panels).
doi:10.1371/journal.pone.0121980.g001
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were considered: MMR-DCF: 44 out of 186, 23.7%; MMR-proficient crypts from Lynch syn-
drome mutation carriers: 34 out of 814, 4.2%; MMR-proficient crypts fromMSS colorectal can-
cer patients: 5 out of 173, 2.9%; p<0.001.
The mutation frequency observed in MMR-DCF was highest for the three non-coding mi-
crosatellite markers BAT25, BAT26, and CAT25, which showed a mutant pattern in 36%, 57%,
and 60% of the analysed MMR-DCF, respectively (Fig. 1B). No significant difference was ob-
served between the three markers.
Among coding microsatellites, the observed mutation frequency ranged between 0% and
33% for the six analysed markers located in the coding regions of the genes AIM2, ACVR2,
BAX,HT001, TAF1B and TGFBR2 (Fig. 1C). Mutations were detected in 5 out of 6 markers
tested, but were absent in TGFBR2. Mutation frequency was highest for the HT001microsatel-
lite (33%) followed by AIM2 (17%) and BAX (10%). For these three markers the difference of
mutation prevalence between MMR-DCF and MMR-proficient crypts was significant: HT001:
7/21 (33%) vs. 0/72 (0%), p<0.0001; AIM2: 4/24 (17%) vs. 2/85 (2%), p = 0.0206; BAX: 2/21
(10%) vs. 0/75 (0%), p = 0.0461. Mutation frequency of non-coding and coding microsatellites
is displayed in Table 1.
From 23 crypt foci evaluable for MSI at non-coding markers, 20 (87%) presented with mu-
tations affecting at least one of the markers BAT25, BAT26, or CAT25. MSI affecting coding
markers was detected in 10 out of 25 (40%) of MMR-DCF. The distribution of coding and
non-coding marker mutation frequency per individual crypt is illustrated in Fig. 3. MMR-DCF
consisting of more than one crypt tended to show a higher frequency of mutations than single-
crypt MMR-DCF, though statistical significance was lacking (23/100 vs. 21/130, p = 0.24, Fish-
er’s exact test).
Fig 2. MMR-DCF prevalence and patient age. Association between age (years) of the patient at operation and prevalence of MMR-DCF (A). The
association of MMR-DCF prevalence with patient age is depicted with a black line adjusted for a colon length of 15 cm; dots represent patients. Estimated
incident rate ratio of colorectal MMR-DCF was 1.75 (95%CI 1.30–2.35) for a change of age at operation of 10 years. The prevalence of MMR-DCF is not
significantly associated with patients’ gender (B) or the MMR gene affected by germline mutation (C).
doi:10.1371/journal.pone.0121980.g002
Table 1. Overview of mutation frequencies of all markers tested. Absolute numbers of crypts examined are followed bymutation percentages.
MMR-proficient crypts from Lynch syndrome patients and MSS colorectal cancer patients were evaluated as controls. P-values were calculated
concerning results of MMR-DCF versus Lynch syndrome crypts.
MMR-DCF MMR-proﬁcient crypts p-value
LS mucosa MSS CRC mucosa
BAT25 8/22 (36%) 12/135 (9%) 3/26 (12%) 0.0018
BAT26 12/21 (57%) 9/121 (7%) 1/25 (4%) <0.0001
CAT25 9/15 (60%) 6/85 (7%) 0/14 (0%) <0.0001
AIM2 4/24 (17%) 2/85 (2%) 1/18 (6%) 0.0206
ACVR2 1/21 (5%) 0/72 (0%) 0/16 (0%) 0.2258
BAX 2/21 (10%) 0/75 (0%) 0/17 (0%) 0.0461
HT001 7/21 (33%) 0/72 (0%) 0/14 (0%) <0.0001
TAF1B 1/20 (5%) 2/90 (2%) 0/24 (0%) 0.4557
TGFBR2 0/21 (0%) 3/79 (4%) 0/19 (0%) 1.000
doi:10.1371/journal.pone.0121980.t001
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Regional diversity of MMR-DCF
To examine the mutational events taking place during the clonal expansion of MMR-deficient
crypts, we examined regional diversity of mutations in MMR-DCF by separately analysing six
regions of one MLH1-negative extended crypt focus from patient LS 4 (extended set). Muta-
tions were only detected in HT001 and AIM2 from all the coding markers, and HT001 pre-
sented with the most heterogeneous mutation pattern. For the non-coding markers, there were
mutations displayed in almost every region of the crypt focus, also differing in the mutation
pattern (S3 Fig.).
Comparison of the mutation frequency in MMR-DCF and MSI-H
colorectal cancer
In order to compare the mutation frequency of selected microsatellite markers between
MMR-DCF and clinically manifest MSI-H adenomas and carcinomas, data for MSI-H colorec-
tal adenoma and cancer were retrieved from SelTarbase [15]. In addition, cancer specimens ob-
tained from the study patients were analysed. As shown in Fig. 4, the mutation prevalence of
the three non-coding microsatellite markers BAT25, BAT26 and CAT25 in MMR-DCF fol-
lowed the same tendency as observed in MSI-H colorectal cancer. CAT25 presented with the
highest mutation rate, followed by BAT26 and BAT25 in both groups. Of the six coding micro-
satellite markers,HT001 presented with the highest mutation frequency in both groups. In
contrast, the most pronounced discrepancies were observed for TAF1B and TGFBR2 (Fig. 4).
Discussion
In the present study, we focused on molecular alterations occurring in MMR-DCF, and their
relation to clinical or histopathological parameters. Our observations confirm the previously
described prevalence of approximately one MMR-DCF per 1 cm2 of mucosa [12].
For the first time, patients with sporadic MSI-H colorectal cancer withMLH1 promoter
hypermethylation were analysed for the presence of MMR-DCF. NoMMR-DCF were observed
in these patients, including the directly tumour-adjacent mucosa, which could be assessed
Fig 3. Distribution of mutation patterns within MMR-DCF. Numbers of microsatellites mutated per MMR-DCF, separately shown for all markers (left
panel), non-coding markers (middle: BAT25, BAT26, and CAT25), and coding markers (right panel: AIM2, ACVR2, BAX, HT001, TAF1B and TGFBR2) are
separately shown. The y-axis represents the percentage of MMR-DCFmutated, whereas the x-axis displays the numbers of microsatellites affected
per lesion.
doi:10.1371/journal.pone.0121980.g003
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from all patients. The lack of MMR-DCF in patients with sporadic MSI-H colorectal cancer
may result from a distinct pathway of tumour development that, in contrast to abrupt loss of
MLH1 in Lynch syndrome-associated lesions, encompasses a gradual decrease of MLH1 pro-
tein expression due to increasing epigenetic changes [23,24]. Our observations suggest that the
occurrence of MMR-DCF is restricted to Lynch syndrome mutation carriers and closely associ-
ated with the presence of MMR gene germline mutations. It is therefore expected that patients
with sporadic MSI-H colorectal cancers that develop cancer as a consequence of two somatic
MMR gene mutations [25–28] will not harbour MMR-deficient crypt foci in the colon mucosa,
similar to our observation in patients withMLH1-hypermethylated cancers. However, so far
no data are available to confirm this assumption. A strong correlation was observed between
patient’s age at operation and the prevalence of MMR-DCF (p<0.001). This finding indicates
an increasing frequency of MMR-DCF in the mucosa from Lynch syndrome mutation carriers
with increasing patients’ age. It is not clear, though, whether this results from accumulation
and persistence of all MMR-DCF formed during life, or whether it reflects a higher rate of le-
sion formation than lesion elimination. An additional factor that might contribute to the accu-
mulation of MMR-DCF in elderly people could be an increasing susceptibility of existing cells
towards developing a mutation due to genomic instability [29]. This question cannot be re-
solved on the basis of the present study, because the cross-sectional study design does not allow
any conclusions on the turnover of MMR-DCF.
In Lynch syndrome patients, colorectal cancer predominantly develops in the proximal
colon [9]. However, a higher frequency of MMR-DCF was observed in Lynch syndrome pa-
tients with distal colorectal cancer localisation. This observation may suggest that in Lynch
Fig 4. Mutation frequency of microsatellite markers. Black bars represent the observed mutation frequency of the respective microsatellites in
MMR-DCF. Mutation frequency reported in the literature for MSI-H colorectal adenoma and carcinoma are displayed by dark grey (adenoma) and white
(carcinoma) bars, respectively. Data for adenomas and carcinomas were retrieved from www.seltarbase.org. Light grey bars indicate mutation frequency in
corresponding carcinomas from the same patients from whom the MMR-DCF were obtained.
doi:10.1371/journal.pone.0121980.g004
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syndrome patients with distal colorectal carcinoma, unidentified factors affecting the carcino-
genesis may also promote the development of MMR-DCF. A potential association between the
number of MMR-DCF and the exposure towards DNA-damaging substances is in fact sug-
gested by a significant increase of mismatch repair-deficient crypts upon temozolomide treat-
ment in a mouse model of Lynch syndrome [30]. The localisation of colorectal cancer to the
proximal or distal colorectum in our study was not related to patients’ age and gender, exclud-
ing these parameters as potential influencing factors.
No significant difference with regard to MMR-DCF prevalence was observed between men
and women. Accordingly, we did not observe any evidence that a difference of MMR-DCF inci-
dence may be responsible for the higher estimated colorectal cancer risk of male compared to
female Lynch syndrome mutation carriers [31,32]. Similarly, MMR-DCF prevalence was iden-
tical between MLH1 and MSH2 mutation carriers, suggesting that the gene affected by germ-
line mutation is not a predictor of MMR-DCF formation.
Immune surveillance may contribute to the recognition of MMR-deficient cells by cytotoxic
T cells, potentially following the generation of MMR deficiency-induced frameshift peptide an-
tigens [33,34]. However, morphological characterisation of MMR-DCF-adjacent mucosal areas
after haematoxylin/eosin and immunohistochemistry staining specific for T cell markers did
not reveal significant alterations of immune infiltration in or around any of the MMR-DCF as-
sessed (S4 Fig.). These results indicate that increased immune cell infiltration was not a general
phenomenon in the vicinity of MMR-DCF. However, the lack of increased immune infiltration
in paraffin-embedded tissue sections does not preclude a functionally relevant, specific local
immune activation. One also has to take into account that immunologic elimination of crypt
foci may take place in a very short time compared to the persistence of MMR-DCF and thereby
escape visual detection. In fact, an enhanced density of mucosal lymphocytes has recently been
described in one MMR-deficient crypt focus [35].
The possibility of examining DNA from individual MMR-deficient crypts opens a window
towards assessing the initial molecular changes occurring after loss of MMR function. Muta-
tion analyses in frame of our previous study had already revealed mutations affecting large,
non-coding microsatellite markers, which are highly prone to insertion/deletion mutations in
the context of MMR deficiency, in the majority of MMR-DCF [12]. In the present study, the
molecular examination of MMR-DCF was largely extended. For the first time, single-crypt
MMR-DCF were examined for molecular alterations. Our results demonstrate mutations of
the three non-coding microsatellite markers BAT25, BAT26, and CAT25 in 40–60% of the
MMR-DCF. In total, 87% of all MMR-DCFs showed a mutation in at least one of the MSI
markers, indicating that the loss of MMR protein expression has immediate functional conse-
quences, already in small and mono-cryptic MMR-DCF. Moreover, they underline the suitabil-
ity of the markers BAT25, BAT26, and CAT25 for the detection of the earliest stages of MMR
deficiency in the colorectum.
For the first time, mutations of several coding microsatellites could be assessed simulta-
neously in MMR-DCF. Five of the six coding microsatellites assessed in this study displayed
mutations in MMR-DCF (AIM2, ACVR2, BAX,HT001, and TAF1B). The highest mutation fre-
quency (33%) in the present study was detected for HT001, followed by AIM2 and BAX. The
observation ofHT001mutations in one third of the analysed MMR-DCF may be compatible
with a potential relevance of the respective gene. A potential tumour-suppressive function of
HT001 is further supported by the high mutation frequency in MSI-H colorectal and endome-
trial cancer [18]. In general, the comparison of coding microsatellite mutation frequencies fol-
low a similar trend in MMR-DCF compared to corresponding MSI-H cancers from the same
patients and to published data for colorectal adenomas and carcinomas [15]. The observed re-
gional heterogeneity in one larger crypt focus (S3 Fig.) suggests that MMR-DCF represent a
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novel model lesion for studying molecular evolution in Lynch syndrome [36,37], and early
events associated with initiation and progression of solid neoplasia in general.
The comparatively high prevalence ofHT001 and AIM2mutations in MMR-DCF is also in-
teresting with regard to frameshift peptide vaccination approaches, which are currently evalu-
ated in MSI-H colorectal cancer patients. The Micoryx vaccine (clinicaltrials.gov,
NCT01461148) encompasses antigens, which result from mutations ofHT001 and AIM2. Con-
sequently, frameshift peptide vaccination may represent a promising approach for tumour pre-
vention in Lynch syndrome mutation carriers.
Interestingly, no mutations of the TGFBR2 coding microsatellite were observed in the pres-
ent study, which is in contrast to our previous study [12], where TGFBR2mutations were de-
tected in larger polycryptic foci. This discrepancy suggests that the occurrence of TGFBR2
mutations is restricted to large MMR-DCF that already show morphological alterations [12].
Hence, TGFBR2mutations represent promising candidate alterations that might contribute to
the progression of MMR-DCF towards malignant transformation of MMR-DCF. Further stud-
ies are needed to validate this hypothesis.
To exclude technical reasons as factors underlying the observed alterations in MMR-DCF
(e.g. related to small amounts of template DNA or formalin fixation), we compared the muta-
tion frequency of microsatellite markers in MMR-DCF and MMR-proficient mucosa from
Lynch syndrome mutation carriers or MSS colorectal cancer patients. The comparison revealed
a low background rate of mutations. The detection of significantly higher rates of mutations in
MMR-DCF clearly argues in favour of MMR deficiency as a biological reason underlying the
detected mutations. Moreover, we were not able to confirm previous reports about a signifi-
cantly higher prevalence of microsatellite mutations in normal mucosa from Lynch syndrome
mutation carriers compared to MSS colorectal cancer control patients [38].
Conclusions
In summary, we here demonstrate for the first time that microsatellite instability is detectable
in the vast majority of MMR-DCF, including monocryptic lesions. Clinically, the occurrence of
MMR-DCF in Lynch syndrome mutation carriers is significantly correlated to age, suggesting
ongoing accumulation of MMR-DCF. Coding microsatellite mutations were observed in
mono- and poly-cryptic MMR-DCF, most frequently affecting HT001, AIM2 and BAX. Muta-
tions of the TGFBR2 gene appear to be restricted to polycryptic MMR-DCF, potentially sug-
gesting that they may favour progression or malignant transformation.
Supporting Information
S1 Fig. Immunohistochemical stains of MMR-DCF. (A) Immunohistochemical stains of all
initial MMR-DCF. Overview of staining results with antibodies specific for the MMR protein
corresponding to the germline mutation of the respective patient. Lesions are denoted by pa-
tient ID and lesion ID. All pictures were taken with a 20x magnification except for LYS 18 (Le-
sion 4) where a 10x magnification was used. (B) Immunohistochemical stains of six additional
MMR-DCF. Lesions are denoted by patient ID and lesion ID and represent resectioning results
of the respective patients. For all pictures a 20x magnification was used.
(TIF)
S2 Fig. Combined overview of all 34 Lynch syndrome patients. This diagram presents all 34
Lynch syndrome patients with patient ID,age at operation, tumour localisation and operation
performed (SC = subtotal colectomy, RH = right hemicolectomy, LH = left hemicolectomy,
AR = anterior rectum resection, SR = sigma resection and TR = total rectum resection). Green
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bars correspond to the primary x-axis displaying total numbers of MMR-DCF (first eleven pa-
tients). Adjacent light blue (men) and light pink (women) bars indicate the measured mucosal
length of the respective patient.
(TIF)
S3 Fig. Regional diversity of MMR-DCF. (A) Regional diversity in non-coding markers
BAT25, BAT26 and CAT25. The observed mutations varied widely between the six regions ex-
amined in this PCR approach for BAT25 (green), BAT26 (blue, filled) and CAT25 (blue).
na = not available. BAT25: Region 1 (-3), Region 2 (-3), Region 3 (-3), Region 4 (wt), Region 5
(-2), Region 6 (-3). BAT26: Region 1 (-4), Region 2 (-6), Region 3 (-3), Region 4 (-3), Region 5
(-3), Region 6 (-4). CAT25: Region 1 (+3), Region 2 (+1), Region 3 (+2), Region 4 (na), Region
5 (wt), Region 6 (-1). (B) Regional diversity in the coding marker HT001. Regional diversity in
the coding marker HT001 for one extensive crypt focus which was divided into six separately
analysed regions. The observed shift mutations were evaluated as follows: Region 1 (-1), Region
2 (-1), Region 3(-2), Region 4 (-1), Region 5 (-1) and Region 6 (-1). (C) Microscopic picture of
lesion 3 (patient LS 4). Objective magnification is 10x. The extensive MMR-DCF was divided
into six separately analysed regions from the left (region 1) to the right (region 6) side.
(TIF)
S4 Fig. Representative example of mucosal immune cells surrounding MMR-DCF. To eval-
uate the local immune infiltration, serial sections were stained with immune cell markers
(CD4, CD8 and FOXP3). No difference in immune cell infiltration was observed in MMR-DCF
and surrounding regions. Immune cell infiltration of MMR-DCF (black arrows) was compared
to two control regions in the vicinity (2 mm and 10 mm distant) of the respective lesion. All
images are shown at 20x magnification.
(TIF)
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